Newsstand | Page 22 | Aplastic Anemia and MDS International Foundation

Newsstand

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation

Originally Published: 01/01/2013
Note: This review is based upon a presentation at the 2012 American Society of Hematology (ASH) Annual Meeting, December 7-10 in Atlanta, Georgia.The full abstract may be reviewed on the ASH Annual Meeting Web site. Search by entering the title in the search box. The abstract number is referenced to access the full report. Abstract #311 Rafael Bejar, MD, PhD1, Kristen E. Stevenson, MS2, Petar Stojanov3, J. Eric Zaneveld4, Michal Bar-Natan5, Bennett Caughey6, Hui Wang, Ph.D.7, Guillermo Garcia-Manero, MD8, Hagop M. Kantarjian, MD9, Corey Cutler, MD, MPH, FRCPC10, Jerome Ritz, MD11,...

Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Report of All 153 Patients Treated in the UK

Originally Published: 01/01/2013
Note: This review is based upon a presentation at the 2012 American Society of Hematology (ASH) Annual Meeting, December 7-10 in Atlanta, Georgia.The full abstract may be reviewed on the ASH Annual Meeting Web site. Search by entering the title in the search box. The abstract number is referenced to access the full report. Poster Presentation Abstract #3472 Anita Hill, Richard J Kelly, Austin G Kulasekararaj, Shreyans A Gandhi, Lindsay D Mitchell, Modupe Elebute, Stephen John Richards, Matthew Cullen, Louise M Arnold, Joanna Large, Alexandra Wood, Gemma L Brooksbank, Tracy Downing, Claire...

Genetic Polymorphism of the Complement Receptor-1 (CR1) Gene Correlates with the Clinical Response to Eculizumab of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Originally Published: 01/01/2013
Note: This review is based upon a presentation at the 2012 American Society of Hematology (ASH) Annual Meeting, December 7-10 in Atlanta, Georgia.The full abstract may be reviewed on the ASH Annual Meeting Web site. Search by entering the title in the search box. The abstract number is referenced to access the full report. Poster Presentation Abstract #983  Tommaso Rondelli, Antonio M. Risitano, Régis Peffault de Latour, Benedetta Peruzzi, Ricci Patrizia, Wilma Barcellini, Anna Paola Iori, Carla Boschetti, Veronica Valle, Veronique Frémeaux-Bacchi, Maria De Angioletti, Gerard Socie, Lucio...

Novel Complement Modulators for Paroxysmal Nocturnal Hemoglobinuria: Peptide and Protein Inhibitors of C3 Convertase Prevent Both Surface C3 Deposition and Subsequent Hemolysis of Affected Erythrocytes in Vitro

Originally Published: 01/01/2013
Note: This review is based upon a presentation at the 2012 American Society of Hematology (ASH) Annual Meeting, December 7-10 in Atlanta, Georgia.The full abstract may be reviewed on the ASH Annual Meeting Web site. Search by entering the title in the search box. The abstract number is referenced to access the full report. Oral Presentation Abstract #370 Antonio M. Risitano, Patrizia Ricci, Caterina Pascariello, Maddalena Raia, Christoph Q Schmidt, Yingxue Li, Edimara S Reis, Michela Sica, Rosario Notaro, Luigi Del Vecchio, Fabrizio Pane, Daniel Ricklin, and John D Lambris Some patients...

Prognostic Relevance of the Kinetics of Worsening of Cytopenias in Lower-Risk MDS: A Substudy from the European Leukemianet Low Risk MDS (EUMDS) Registry

Originally Published: 01/01/2013
Note: This review is based upon a presentation at the 2012 American Society of Hematology (ASH) Annual Meeting, December 7-10 in Atlanta, Georgia.The full abstract may be reviewed on the ASH Annual Meeting Web site. Search by entering the title in the search box. The abstract number is referenced to access the full report. Abstract # 700 Raphael Itzykson1, Alex Smith2, Theo M. de Witte3, Jackie Droste4, Reinhard Stauder5, Argyris Symeonidis6, Eva Hellstrom-Lindberg, MD7, Guillermo Sanz8, Jaroslav Cermak, MD, PhD9, Otilia Georgescu10, Mette Skov-Holm11, Ulrich Germing, MD12, Marius...

Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes

Originally Published: 01/01/2013
Note: This review is based upon a presentation at the 2012 American Society of Hematology (ASH) Annual Meeting, December 7-10 in Atlanta, Georgia.The full abstract may be reviewed on the ASH Annual Meeting Web site. Search by entering the title in the search box. The abstract number is referenced to access the full report. Abstract #424 Guillermo Garcia-Manero, MD1, Steven D. Gore, MD2, Suman Kambhampati, MD3*, Bart L Scott, MD, MS4, Ayalew Tefferi, MD5, Christopher R Cogle, MD6, William Edenfield, MD7*, Joel Hetzer, PhD8*, Keshava Kumar, PhD8* and Barry S. Skikne, MD9 Treatment for...

Infections in myelodysplastic syndromes: a review

Originally Published: 10/31/2012
Infections are a significant cause of morbidity and mortality in patients with MDS accounting for approximately 38% of all deaths in untreated cases, more so than that resulting from MDS progression to acute myeloid leukemia (AML). Although there is accumulating data on the risk factors and types of infections in MDS patients, interpretation of the available data has been challenging. This stems from several reasons and includes data reporting from different sources, year of study, and use of novel treatment regimens in the last decade, and transplant-related immune defects in those...

New therapeutics for myelodysplastic syndromes

Originally Published: 10/31/2012
In recent years, several therapeutic agents have been approved for treatment of patients with myelodysplastic syndromes (MDS), including lenalidomide (Revlimidâ) and the azanucleosides, azacitidine (Vidazaâ) and decitabine (Dacogenâ).  Although these agents represent a significant step forward in the management of MDS, there remains a definitive need for further progress.  In his review, “New therapeutics for myelodysplastic syndromes,” Dr. List outlines the rationale for MDS-directed drug development efforts and describes several emerging agents currently or soon to be studied in clinical...

Prediction of outcomes after allogeneic stem cell transplantation for myelodysplastic syndromes

Originally Published: 09/27/2012
Allogeneic bone marrow transplantation (aBMT; i.e., a bone marrow transplantation whereby the donor is not genetically related to the recipient) is still the only potential cure for MDS patients.  However, an aBMT may cause serious complications, some of which may result in death.  In other cases, MDS will come back.  The aim of this study was to identify patient characteristics that would predict survival in MDS patients after an aBMT. A retrospective study (i.e., a study in which patient’s disease characteristics and history are investigated going back in time) showed that of the many...

Therapy-related Myelodysplastic Syndrome: an analysis of 5 risk models in patients treated with azacitidine

Originally Published: 09/27/2012
Myelodysplastic syndrome (MDS) is a disease mostly associated with old age, however, it can also occur as a complication of anti-cancer treatment, including certain chemotherapies and/or radiation.  This is called therapy-related MDS (t-MDS).  When it happens it is often an aggressive disease and difficult to treat.  MDS is a very heterogeneous group of diseases and to determine what the best treatment option is for a particular patient is challenging.  Doctors are helped in this process by scoring systems that, based on the characteristics of the patient’s disease, help evaluate the...